DDInter1585 DDInter1729
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaprozin {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Sulindac
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) Sulindac
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminocaproic acid
Aminocaproic acid {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Sulindac
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaprozin {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Reteplase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Oxaprozin {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Sulindac
Reteplase {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Fondaparinux {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Sulindac
Reteplase {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Reteplase {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Sulindac (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) binds PPARD (Gene) and Treprostinil (Compound) upregulates PPARD (Gene) and PPARD (Gene) is bound by Sulindac (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Aminocaproic acid and Aminocaproic acid (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Sulindac (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Sulindac (Compound)
Reteplase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Sulindac (Compound)
Reteplase may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Reteplase may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)